Day: May 7, 2020

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has entered into an agreement with Creapharm Clinical Supplies (“Creapharm”), a leader in clinical trial supply services, for the packaging, labelling and distribution of Phase 2 clinical trial drug product supply of its MS1819 therapy for the treatment of exocrine pancreatic insufficiency (EPI). Under the terms of the agreement, Creapharm will package, label, provide qualified person (QP) release and distribute AzurRx’s MS1819 clinical trial drug product for both the upcoming Phase 2b OPTION 2 Monotherapy and the ongoing Phase 2 Combination Therapy clinical trials for the treatment of EPI...

CINCINNATI, May 07, 2020 (GLOBE NEWSWIRE) — Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the first quarter ended March 31, 2020, and provided a business update.“We continue to be excited about our glaucoma program,” said Joseph Gardner, President and Founder.  “The statistically significant reductions in intraocular pressure (IOP) together with the favorable tolerability profile observed in the Phase 1b study in combination with standard of care prostaglandin therapy were very encouraging. We look forward to continuing to evaluate razuprotafib  in the planned 28-day Phase 2 open angle glaucoma (OAG) study which we currently expect to initiate in the third...

CINCINNATI, May 07, 2020 (GLOBE NEWSWIRE) — Protech Home Medical Corp. (the “Company”) (TSXV: PTQ), a ‎healthcare services company with operations in the U.S., today announced that it will host its Q2 2020 earnings conference call and audio webcast on Wednesday, May 20, 2020 at 10:00 a.m. (EDT).Conference Call Details:Wednesday, May 20, 2020 at 10:00 a.m. (EDT).Canada/US Toll Free: 1 (800) 319 4610International: 1 (604) 638 5340Audio Webcast Details:The live audio webcast can be found on the investor section of the Company’s website through the following link:https://www.protechhomemedical.com/conference_calls.php#“I am very pleased to offer current and future interested participants an audio webcast option, along with the standard telephone dial-in for our Q2 2020 earnings call and subsequent quarters,” said CEO and Chairman Greg...

IRVINE, Calif., May 07, 2020 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results for its 2020 first quarter, which ended March 31, 2020, on Tuesday, May 12, 2020 after the market close.Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada. Callers should dial in at least 5 minutes prior to the call start time.A live and archived webcast may be accessed by visiting the company’s website at www.clearpointneuro.com, by selecting “Investors” / “News” / “IR Calendar.”A replay of the conference call will be available shortly after completion of the call until May 28, 2020, by calling (877) 660-6853, or (201) 612-7415 if calling...

TORONTO, May 07, 2020 (GLOBE NEWSWIRE) — Compass Gold Corp. (TSX-V: CVB) (Compass or the Company) is pleased to provide an update on the recently completed drilling and ongoing shallow soil geochemistry exploration work at the Tarabala and Sodala prospect areas, located on the Company’s Sikasso Property in Southern Mali (Figure 1).HighlightsAir core (AC) drilling at Tarabala (26 RC holes, 1,435 m) intersected gold mineralization within the 10-km long Tarabala soil geochemistry trendBest interval at Tarabala was 16 m at 1.51 g/t Au (from 16 m), including 4 m @ 5.20 g/t Au (from 26m)Drilling at the Sodala artisanal workings intersected NE-trending structure containing five narrow gold zones in one hole (SAAC031), including 1 m at 2.71 g/t Au (from 16 m)An AC drill program of at least 2,500 m will commence immediately, starting with...

$40.3 million revenue$5.0 million net income$17.8 million EBITDANo significant debt maturities until 2023MONACO, May 07, 2020 (GLOBE NEWSWIRE) — Navios Maritime Containers L.P. (“Navios Containers” or the “Company”) (NASDAQ: NMCI), a growth vehicle dedicated to the container sector of the maritime industry, today reported its financial results for the first quarter ended March 31, 2020.Angeliki Frangou, Chairman and Chief Executive Officer, stated, “While the humanitarian crises caused by the pandemic has been heart breaking, we have also been strengthened by the courage and compassion of the first responders, particularly the many dedicated health care workers. At any given time, our vessels carry about 1,000 people. Keeping these people safe and these vessels moving in and out of quarantined countries, with ever-changing...

RAMSEY, N.J. and BOCA RATON, Fla., May 07, 2020 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immuno-deficient patients at risk for infection and others at risk for certain infectious diseases, today announced several recent corporate achievements pertaining to its supply chain robustness objectives as established at the beginning of 2020.“We have been very active during these challenging times in executing upon what we believe to be high value-added improvements to our supply chain to enhance robustness, increase capacity and heighten control over the production of our products.  These achievements include the successful manufacturing of three BIVIGAM®...

SAN DIEGO and TORONTO, May 07, 2020 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company will participate in and hold investor meetings at the RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020.Conference Presentation Details:Date:               Wednesday, May 20, 2020Time:               3:40 – 4:05 pm EDTLocation:         Virtual, Fireside ChatWebcast:         linkThe webcast and presentation will be archived shortly after the live event and will be available on the Aptose website here. About Aptose BiosciencesAptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet...

— Commercial preparations advancing, with topline PEDFIC 1 results expected mid-2020  —— First sites initiated for second pivotal trial in biliary atresia —— Management to host conference call and webcast today at 10:00 a.m. ET —BOSTON, May 07, 2020 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the first quarter ended March 31, 2020.“Despite the unprecedented challenges of COVID-19, our fundamentals remain unchanged, and we continue to make significant progress across our development programs, while accelerating preparations for commercialization,” said Ron Cooper, President and Chief Executive Officer of Albireo. “In PFIC, we are now months away from our Phase...

Today, The Drilling Company of 1972 A/S (“Maersk Drilling”) provides the following update on the impact of COVID-19 and lower oil prices.Revised financial guidance for 2020On 20 March 2020, Maersk Drilling revised its profitability guidance for 2020 for EBITDA before special items to USD 325-375m. Since then, oil and gas companies have announced further reductions in spending budgets and sanctioning of new projects and ongoing tenders have been postponed or cancelled. Further, certain existing contracts have been renegotiated, suspended or terminated.Consequently, Maersk Drilling has re-assessed the commercial and operational assumptions underlying the financial forecasts for 2020 and revises its guidance for 2020 for EBITDA before special items to USD 250-300m (previous guidance of USD 325-375m). The guidance for capital expenditures...